5 Worst Blue Chip Stocks to Buy Now

In this article, we will list the 5 Worst Blue Chip Stocks to Buy Now. Please visit 8 Worst Blue Chip Stocks to Buy Now if you would like to see the extended list and the methodology behind it.

5. Intuitive Surgical, Inc. (NASDAQ:ISRG)

On July 9, 2026, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical, Inc. (NASDAQ:ISRG) with an Outperform rating and $518 price target. Chopra said the da Vinci 5 upgrade cycle remains in the early innings, procedure growth is broadening into new specialties and geographies, and the earnings stream is “durable and visible.”

On July 6, Evercore ISI lowered the firm’s price target on Intuitive Surgical to $430 from $480 and kept an In Line rating on the shares. Evercore ISI said its Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector.

Last month, BofA analyst Travis Steed lowered the firm’s price target on Intuitive Surgical to $515 from $520 and kept a Buy rating on the shares. Steed noted that BofA’s services team continues to highlight a lower utilization environment and took a more conservative view on 2027 medtech company estimates, given that valuations already reflect utilization risk. Steed also assumed inflation will be more of a headwind in 2027, with less margin expansion for medtech, and lowered 2027 estimates across the firm’s larger-cap coverage with exposure to utilization and inflation.

Intuitive Surgical, Inc. (NASDAQ:ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.